ophthalmologyadvisor12d
FDA Approves Wearable Infusion Device for Advanced Parkinson Disease
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
Chosunbiz17d
Korean firms innovate Parkinson's treatment with new drugs, FDA approvals
The recently approved Onapgo also aims to treat motor fluctuation symptoms in adult patients with advanced Parkinson's disease, but it is the first wearable apomorphine subcutaneous infusion device.
Yahoo Finance18d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...
Taiwan News18d
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with ...
Nasdaq18d
FDA Approves ONAPGO Apomorphine Hydrochloride For Parkinson's Disease Treatment
(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations ...
Finanznachrichten18d
Supernus Pharmaceuticals, Inc.: Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
ONAPGO (apomorphine hydrochloride) injection, for subcutaneous use, is available in a 98 mg/20 mL (4.9 mg/mL) apomorphine hydrochloride solution. 1 ONAPGO. Package insert. Supernus Pharmaceuticals ...
Nasdaq18d
Supernus Pharmaceuticals Announces FDA Approval of ONAPGO, the First Subcutaneous Apomorphine Infusion Device for Parkinson's Disease in the U.S.
approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...
The American Journal of Managed Care19d
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease. The FDA has approved apomorphine hydrochloride injection (Onapgo), the first and only ...
MedCity News19d
Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval
Apomorphine mimics dopamine, binding to receptors responsible for motor control. An FDA-approved injectable version of this drug has been available for more than 20 years for treating the off epis ...
MedPage Today19d
FDA OKs New Wearable Treatment for Parkinson's Disease
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with ...